182 related articles for article (PubMed ID: 38713943)
41. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
42. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
[TBL] [Abstract][Full Text] [Related]
43. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis.
Zhang L; She ZG; Li H; Zhang XJ
Clin Sci (Lond); 2020 Jul; 134(13):1775-1799. PubMed ID: 32677680
[TBL] [Abstract][Full Text] [Related]
44. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus. II. Treatment].
Pár A; Wittmann I; Pár G
Orv Hetil; 2022 May; 163(22):855-862. PubMed ID: 35895614
[TBL] [Abstract][Full Text] [Related]
45. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis.
Liu Q; Yu J; Wang L; Tang Y; Zhou Q; Ji S; Wang Y; Santos L; Haeusler RA; Que J; Rajbhandari P; Lei X; Valenti L; Pajvani UB; Qin J; Qiang L
J Hepatol; 2020 Aug; 73(2):361-370. PubMed ID: 32135178
[TBL] [Abstract][Full Text] [Related]
47. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
48. An herbal formulation "Shugan Xiaozhi decoction" ameliorates methionine/choline deficiency-induced nonalcoholic steatohepatitis through regulating inflammation and apoptosis-related pathways.
Wang S; Chen B; Du R; Zhong M; Zhang C; Jin X; Cui X; Zhou Y; Kang Q; Xu H; Li Y; Wu Q; Tong G; Luo L
J Ethnopharmacol; 2024 Jul; 329():118127. PubMed ID: 38583728
[TBL] [Abstract][Full Text] [Related]
49. Promising therapies for treatment of nonalcoholic steatohepatitis.
Noureddin M; Zhang A; Loomba R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
[TBL] [Abstract][Full Text] [Related]
50. Paeonol attenuates nonalcoholic steatohepatitis by regulating intestinal flora and AhR/NLRP3/Caspase-1 metabolic pathway.
Yan G; Zhang L; Wu D; Jiang S; Wu Q; Dai M
J Ethnopharmacol; 2024 Jul; 329():118147. PubMed ID: 38574779
[TBL] [Abstract][Full Text] [Related]
51. Ferroptotic Cell Death: New Regulatory Mechanisms for Metabolic Diseases.
Le Y; Zhang Z; Wang C; Lu D
Endocr Metab Immune Disord Drug Targets; 2021; 21(5):785-800. PubMed ID: 32735532
[TBL] [Abstract][Full Text] [Related]
52. Protective effects of scutellaria-coptis herb couple against non-alcoholic steatohepatitis via activating NRF2 and FXR pathways in vivo and in vitro.
Xue Y; Wei Y; Cao L; Shi M; Sheng J; Xiao Q; Cheng Z; Luo T; Jiao Q; Wu A; Chen C; Zhong L; Zhang C
J Ethnopharmacol; 2024 Jan; 318(Pt A):116933. PubMed ID: 37482263
[TBL] [Abstract][Full Text] [Related]
53. The Potential of Lamiaceae Herbs for Mitigation of Overweight, Obesity, and Fatty Liver: Studies and Perspectives.
Diab F; Zbeeb H; Baldini F; Portincasa P; Khalil M; Vergani L
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956991
[TBL] [Abstract][Full Text] [Related]
54. Integrated blood and organ profile analysis to evaluate ameliorative effects of kaempferol on 5-fluorouracil-induced toxicity.
Sharma A; Chorawala MR; Rawal RM; Shrivastava N
Sci Rep; 2024 Jan; 14(1):2363. PubMed ID: 38287048
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review.
Kaur S; Sojitra V; Zahra A; Hutchinson J; Folawemi O; Bittla P; Ramphall S
Cureus; 2023 Sep; 15(9):e45789. PubMed ID: 37745748
[TBL] [Abstract][Full Text] [Related]
56. Mechanisms of Kaempferol in the treatment of diabetes: A comprehensive and latest review.
Yang Y; Chen Z; Zhao X; Xie H; Du L; Gao H; Xie C
Front Endocrinol (Lausanne); 2022; 13():990299. PubMed ID: 36157449
[TBL] [Abstract][Full Text] [Related]
57. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
58. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
59. 20 years of leptin: leptin in common obesity and associated disorders of metabolism.
DePaoli AM
J Endocrinol; 2014 Oct; 223(1):T71-81. PubMed ID: 24973357
[TBL] [Abstract][Full Text] [Related]
60. Exploring the mechanisms of kaempferol in neuroprotection: Implications for neurological disorders.
Nezhad Salari AM; Rasoulizadeh Z; Shabgah AG; Vakili-Ghartavol R; Sargazi G; Gholizadeh Navashenaq J
Cell Biochem Funct; 2024 Mar; 42(2):e3964. PubMed ID: 38439154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
